Jefferies Financial Group Begins Coverage on Kala Pharmaceuticals (KALA)
Jefferies Financial Group assumed coverage on shares of Kala Pharmaceuticals (NASDAQ:KALA) in a research note released on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $15.00 price target on the stock.
KALA has been the subject of several other research reports. HC Wainwright reissued a buy rating and set a $15.00 price target on shares of Kala Pharmaceuticals in a research report on Thursday, December 27th. Zacks Investment Research downgraded Kala Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, January 22nd. BidaskClub raised Kala Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, February 20th. Wedbush set a $51.00 price target on Kala Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, January 16th. Finally, JPMorgan Chase & Co. dropped their price target on Kala Pharmaceuticals from $35.00 to $22.00 and set an overweight rating for the company in a research report on Wednesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $20.58.
Kala Pharmaceuticals stock opened at $8.67 on Thursday. The company has a quick ratio of 6.27, a current ratio of 6.34 and a debt-to-equity ratio of 0.30. The firm has a market cap of $285.06 million, a price-to-earnings ratio of -3.50 and a beta of 1.73. Kala Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $18.30.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.